113 related articles for article (PubMed ID: 23023200)
1. Benefit-risk balance of reoperation for persistent medullary thyroid cancer.
Machens A; Dralle H
Ann Surg; 2013 Apr; 257(4):751-7. PubMed ID: 23023200
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
Machens A; Dralle H
J Clin Endocrinol Metab; 2010 Jun; 95(6):2655-63. PubMed ID: 20339026
[TBL] [Abstract][Full Text] [Related]
3. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
4. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
Machens A; Lorenz K; Dralle H
Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
[TBL] [Abstract][Full Text] [Related]
5. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.
Weber T; Schilling T; Frank-Raue K; Colombo-Benkmann M; Hinz U; Ziegler R; Klar E
Surgery; 2001 Dec; 130(6):1044-9. PubMed ID: 11742336
[TBL] [Abstract][Full Text] [Related]
6. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
Scollo C; Baudin E; Travagli JP; Caillou B; Bellon N; Leboulleux S; Schlumberger M
J Clin Endocrinol Metab; 2003 May; 88(5):2070-5. PubMed ID: 12727956
[TBL] [Abstract][Full Text] [Related]
7. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis.
Machens A; Gimm O; Ukkat J; Hinze R; Schneyer U; Dralle H
Cancer; 2000 Apr; 88(8):1909-15. PubMed ID: 10760769
[TBL] [Abstract][Full Text] [Related]
8. Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis.
Rowland KJ; Jin LX; Moley JF
Ann Surg Oncol; 2015 Jan; 22(1):96-102. PubMed ID: 25234024
[TBL] [Abstract][Full Text] [Related]
9. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
[TBL] [Abstract][Full Text] [Related]
10. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
Mirallié E; Iacobone M; Sebag F; Henry JF
Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
[TBL] [Abstract][Full Text] [Related]
11. Prediction of biochemical cure in patients with medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
Br J Surg; 2020 May; 107(6):695-704. PubMed ID: 32108330
[TBL] [Abstract][Full Text] [Related]
12. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma.
Gimm O; Ukkat J; Dralle H
World J Surg; 1998 Jun; 22(6):562-7; discussion 567-8. PubMed ID: 9597929
[TBL] [Abstract][Full Text] [Related]
13. Biological relevance of medullary thyroid microcarcinoma.
Machens A; Dralle H
J Clin Endocrinol Metab; 2012 May; 97(5):1547-53. PubMed ID: 22399508
[TBL] [Abstract][Full Text] [Related]
14. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Aug; 99(8):2986-94. PubMed ID: 24840813
[TBL] [Abstract][Full Text] [Related]
15. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
[TBL] [Abstract][Full Text] [Related]
16. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method.
Dralle H; Damm I; Scheumann GF; Kotzerke J; Kupsch E
Henry Ford Hosp Med J; 1992; 40(3-4):264-7. PubMed ID: 1362420
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer.
Kebebew E; Kikuchi S; Duh QY; Clark OH
Arch Surg; 2000 Aug; 135(8):895-901. PubMed ID: 10922248
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?
Machens A; Hauptmann S; Dralle H
J Clin Endocrinol Metab; 2008 Jun; 93(6):2234-8. PubMed ID: 18364379
[TBL] [Abstract][Full Text] [Related]
19. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level.
Machens A; Schneyer U; Holzhausen HJ; Dralle H
J Clin Endocrinol Metab; 2005 Apr; 90(4):2029-34. PubMed ID: 15634717
[TBL] [Abstract][Full Text] [Related]
20. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
